Saturday, 08 August 2020


Evolva, Ajinomoto enter development deal

24 January 2013 | News | By BioSpectrum Bureau

Evolva Holding and Ajinomoto to jointly develop novel fermentation production routes

Evolva Holding and Ajinomoto to jointly develop novel fermentation production routes

Singapore: Evolva Holding SA entered into a collaboration agreement with Ajinomoto, Japan, for the joint development of novel fermentation production routes for a natural functional ingredient for application in personal care.

During the three-and-a-half year collaboration, Ajinomoto will fund R&D activities at Evolva, focused initially on building a novel and valuable pathway with Evolva's fermentation technology and subsequently on improving production yield through the scale-up and manufacturing phases.

During the collaboration, seven full-time scientists at Evolva are expected to work on the program. Evolva will receive an upfront exclusivity and technology access fee as well as monthly research fees. In addition, Evolva will receive milestone payments upon achieving certain goals in terms of yield, productivity and production costs.

The total fees and milestone payments to Evolva during the collaboration will amount to more than CHF 10 million. In case of commercialisation, Evolva will receive a royalty as a percentage on product sold.

Dr Panchapagesa Murali, CEO, Evolva India, said: "We value highly the confidence in our capabilities that Ajinomoto Co is showing by entering into this collaboration. We look forward to providing Ajinomoto Co with efficient production routes for their important product. For Evolva, this project has long-term benefits as it allows us to build a pathway which can be important for other products."


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls